Authors:	Kayki-Mutlu, Gizem Michel, Martin C.
Title:	A year in pharmacology : new drugs approved by the US Food and Drug Administration in 2020
Online publication date:	23-Aug-2022
Year of first publication:	2021
Language:	english
Abstract:	While the COVID-19 pandemic also affected the work of regulatory authorities, the US Food and Drug Administration approved a total of 53 new drugs in 2020, one of the highest numbers in the past decades. Most newly approved drugs related to oncology (34%) and neurology (15%). We discuss these new drugs by level of innovation they provide, i.e., first to treat a condition, first using a novel mechanisms of action, and “others.” Six drugs were first in indication, 15 first using a novel mechanism of action, and 32 other. This includes many drugs for the treatment of orphan indications and some for the treatment of tropical diseases previously neglected for commercial reasons. Small molecules continue to dominate new drug approvals, followed by antibodies. Of note, newly approved drugs also included small-interfering RNAs and antisense oligonucleotides. These data show that the trend for declines in drug discovery and development has clearly been broken.
DDC:	610 Medizin 610 Medical sciences
Institution:	Johannes Gutenberg-Universität Mainz
Department:	FB 04 Medizin
Place:	Mainz
ROR:	https://ror.org/023b0x485
DOI:	http://doi.org/10.25358/openscience-7606
Version:	Published version
Publication type:	Zeitschriftenaufsatz
License:	CC BY
Information on rights of use:	https://creativecommons.org/licenses/by/4.0/
Journal:	Naunyn-Schmiedeberg's archives of pharmacology 394
Pages or article number:	839 852
Publisher:	Springer
Publisher place:	Berlin u.a.
Issue date:	2021
ISSN:	1432-1912
Publisher DOI:	10.1007/s00210-021-02085-3
Appears in collections:	JGU-Publikationen